Article(id=1329837540615500591, tenantId=1146029695717560320, journalId=1319690329412173987, issueId=1329837471875051704, articleNumber=null, orderNo=null, doi=10.13683/j.wph.2024.03.013, pmid=null, cstr=null, oa=null, hot=null, price=null, onlineType=0, articleFormat=0, articleType=null, articleTypeStr=null, receivedDate=1691078400000, receivedDateStr=2023-08-04, revisedDate=null, revisedDateStr=null, acceptedDate=null, acceptedDateStr=null, onlineDate=1794987576868, onlineDateStr=2026-11-18, pubDate=1710000000000, pubDateStr=2024-03-10, doiRegisterDate=null, doiRegisterDateStr=null, onlineIssueDate=1794987576868, onlineIssueDateStr=2026-11-18, onlineJustAcceptDate=null, onlineJustAcceptDateStr=null, onlineFirstDate=null, onlineFirstDateStr=null, sourceXml=null, magXml=null, createTime=1794987576868, creator=13701087609, updateTime=1794987576868, updator=13701087609, issue=Issue{id=1329837471875051704, tenantId=1146029695717560320, journalId=1319690329412173987, year='2024', volume='45', issue='3', pageStart='233', pageEnd='344', issueExtLink='null', onlineDate='null', pubDate='1710000000000', pubDateStr='2024-03-10', beforeIssueId=null, nextIssueId=null, price=null, status=1, issueComplete=1, articleOrder=1, issueType=-1, specialIssue=null, createTime=1794987560480, creator='13701087609', updateTime=1794988245359, updator='13701087609', preIssue=null, nextIssue=null, articleTotal=null, ext={EN=IssueExt(id=1329840345090732938, tenantId=1146029695717560320, journalId=1319690329412173987, issueId=1329837471875051704, language=EN, specialIssueTitle=, coverIllustrator=null, specialIssueEditor=, specialIssueAbout=), CN=IssueExt(id=1329840345090732939, tenantId=1146029695717560320, journalId=1319690329412173987, issueId=1329837471875051704, language=CN, specialIssueTitle=, coverIllustrator=null, specialIssueEditor=, specialIssueAbout=)}, issueFiles=null, downloadFileDto=null}, startPage=317, endPage=323, ext={EN=ArticleExt(id=1329837540837798704, articleId=1329837540615500591, tenantId=1146029695717560320, journalId=1319690329412173987, language=EN, title=Rapid health technology assessment of lorlatinib in the first-line treatment of anaplastic lymphoma kinase mutation-positive non-small cell lung cancer, columnId=1325221089055486019, journalTitle=World Clinical Drug, columnName=Article, runingTitle=null, highlight=null, articleAbstract=
Objective

To evaluate the safety, efficacy and economy of lorlatinib as the first-line treatment in patients with anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC) by rapid health technology assessment (rHTA), and to provide evidence for clinical decision makers.

Methods

Domestic and foreign databases and other major official HTA websites were used, and the related literatures about lorlatinib as first-line treatment for ALK mutation-positive NSCLC patients were included and comprehensively analyzed.

Results

A total of 9 systematic/meta-analyses and 4 economic studies were included. Efficacy results showed that objective response rate and progression-free survival of lorlatinib were significantly better than other ALK-tyrosine kinase inhibitors and chemicals, but overall survival was not significantly different. Safety results showed that the incidence of adverse events of lorlatinib≥3 was only lower than ceritinib, but controllable. Economic results did not show a significant cost-effectiveness advantage.

Conclusion

Lorlatinib has efficacy and safety advantages in the first-line treatment of ALK mutation-positive NSCLC patients, but its economic advantages need to be further studied. More safety, effectiveness and economic studies focusing on intuitive comparison and multi-subgroup are necessary.

, authors=Yuting YAN, Jieyu SUN, Qian LI*, authorsList=Yuting YAN, Jieyu SUN, Qian LI, authorCompany=null, correspAuthors=Qian LI, authorNote=null, correspAuthorsNote=null, copyrightStatement=null, copyrightOwner=null, extLink=null, articleAbsUrl=null, sourceXml=null, magXml=null, pdfUrl=null, pdf=null, pdfFileSize=null, pdfExtLink=null, richHtmlUrl=null, mobilePdfUrl=null, reviewReport=null, pdfFirstPage=null, abstractGraph=null, abstractGraphContent=null, abstractVideo=null, citation=null, cebUrl=null, magXmlContent=null, mapNumber=null, fund=null), CN=ArticleExt(id=1329837541139788593, articleId=1329837540615500591, tenantId=1146029695717560320, journalId=1319690329412173987, language=CN, title=洛拉替尼一线治疗间变性淋巴瘤激酶突变阳性非小细胞肺癌患者的快速卫生技术评估, columnId=1325221089235841093, journalTitle=世界临床药物, columnName=研究论文, runingTitle=null, highlight=null, articleAbstract=
目的

应用快速卫生技术评估(rapid health technology assessment,rHTA)对洛拉替尼一线治疗间变性淋巴瘤激酶(anaplastic lymphoma kinase,ALK)突变阳性非小细胞肺癌(non-small cell lung cancer,NSCLC)患者的安全性、有效性及经济性进行评估,为临床决策者提供药品遴选循证依据。

方法

检索国内外数据库及全球各大HTA官方网站,纳入洛拉替尼一线治疗ALK突变阳性NSCLC患者相关文献,并进行综合性分析。

结果

共纳入9篇系统评价/meta分析、4篇经济学研究。有效性结果显示,洛拉替尼客观缓解率和无进展生存期显著优于其他ALK-酪氨酸激酶抑制剂和化学药物,但总生存率无显著差异;安全性结果显示,洛拉替尼≥3级不良反应事件发生率仅低于塞瑞替尼,但均可控;经济性结果未显示出显著成本-效果优势。

结论

洛拉替尼一线治疗ALK突变阳性NSCLC患者具有有效性、安全性优势,但其经济性优势需进一步研究,未来有必要开展更直观的比较,并进行多亚组的安全性、有效性及经济性研究。

, authors=闫雨婷, 孙洁雨, 李茜*, authorsList=闫雨婷, 孙洁雨, 李茜, authorCompany=null, correspAuthors=李茜, authorNote=

闫雨婷,主管药师,研究方向:抗肿瘤药物合理应用。

孙洁雨,主管药师,研究方向:循证药学。

, correspAuthorsNote=
李茜,主管药师,研究方向:医院药学。
, copyrightStatement=null, copyrightOwner=null, extLink=null, articleAbsUrl=null, sourceXml=1Ltlet+AF+sUHynnZ+Zd6g==, magXml=WdWPV4HPZcEkWlqQ59/zpA==, pdfUrl=null, pdf=CBTYpKmJUWmdaf+lKqTEVw==, pdfFileSize=1690208, pdfExtLink=null, richHtmlUrl=null, mobilePdfUrl=null, reviewReport=null, pdfFirstPage=null, abstractGraph=null, abstractGraphContent=null, abstractVideo=null, citation=null, cebUrl=null, magXmlContent=864QY25jJdTd33gfsE/e6Q==, mapNumber=null, fund=null)}, authors=[Author(id=1329837541496304438, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329837540615500591, orderNo=0, firstName=null, middleName=null, lastName=null, nameCn=null, orcid=null, stid=null, country=null, authorPic=null, dead=0, email=null, emailSecond=null, emailThird=null, correspondingAuthor=0, authorType=1, ext={EN=AuthorExt(id=1329837541571801912, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329837540615500591, authorId=1329837541496304438, language=EN, stringName=Yuting YAN, firstName=Yuting, middleName=null, lastName=YAN, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=null, address=Department of Pharmacy, the First Affiliated Hospital of Nanjing Medical University, Nanjing 210029, Jiangsu Province, China, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null), CN=AuthorExt(id=1329837541672465209, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329837540615500591, authorId=1329837541496304438, language=CN, stringName=闫雨婷, firstName=null, middleName=null, lastName=null, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=null, address=南京医科大学附属第一医院药学部,江苏 南京 210029, bio={"content":"

闫雨婷,主管药师,研究方向:抗肿瘤药物合理应用。

"}, bioImg=null, bioContent=

闫雨婷,主管药师,研究方向:抗肿瘤药物合理应用。

, aboutCorrespAuthor=null)}, companyList=[AuthorCompany(id=1329837541408224050, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329837540615500591, xref=null, ext=[AuthorCompanyExt(id=1329837541416612659, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329837540615500591, companyId=1329837541408224050, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=Department of Pharmacy, the First Affiliated Hospital of Nanjing Medical University, Nanjing 210029, Jiangsu Province, China), AuthorCompanyExt(id=1329837541429195572, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329837540615500591, companyId=1329837541408224050, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=南京医科大学附属第一医院药学部,江苏 南京 210029)])]), Author(id=1329837543295660859, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329837540615500591, orderNo=1, firstName=null, middleName=null, lastName=null, nameCn=null, orcid=null, stid=null, country=null, authorPic=null, dead=0, email=null, emailSecond=null, emailThird=null, correspondingAuthor=0, authorType=1, ext={EN=AuthorExt(id=1329837543387935550, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329837540615500591, authorId=1329837543295660859, language=EN, stringName=Jieyu SUN, firstName=Jieyu, middleName=null, lastName=SUN, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=null, address=Department of Pharmacy, the First Affiliated Hospital of Nanjing Medical University, Nanjing 210029, Jiangsu Province, China, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null), CN=AuthorExt(id=1329837543530541887, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329837540615500591, authorId=1329837543295660859, language=CN, stringName=孙洁雨, firstName=null, middleName=null, lastName=null, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=null, address=南京医科大学附属第一医院药学部,江苏 南京 210029, bio={"content":"

孙洁雨,主管药师,研究方向:循证药学。

"}, bioImg=null, bioContent=

孙洁雨,主管药师,研究方向:循证药学。

, aboutCorrespAuthor=null)}, companyList=[AuthorCompany(id=1329837541408224050, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329837540615500591, xref=null, ext=[AuthorCompanyExt(id=1329837541416612659, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329837540615500591, companyId=1329837541408224050, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=Department of Pharmacy, the First Affiliated Hospital of Nanjing Medical University, Nanjing 210029, Jiangsu Province, China), AuthorCompanyExt(id=1329837541429195572, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329837540615500591, companyId=1329837541408224050, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=南京医科大学附属第一医院药学部,江苏 南京 210029)])]), Author(id=1329837543652176705, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329837540615500591, orderNo=2, firstName=null, middleName=null, lastName=null, nameCn=null, orcid=null, stid=null, country=null, authorPic=null, dead=0, email=null, emailSecond=null, emailThird=null, correspondingAuthor=1, authorType=1, ext={EN=AuthorExt(id=1329837543731868483, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329837540615500591, authorId=1329837543652176705, language=EN, stringName=Qian LI, firstName=Qian, middleName=null, lastName=LI, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=*, address=Department of Pharmacy, the First Affiliated Hospital of Nanjing Medical University, Nanjing 210029, Jiangsu Province, China, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null), CN=AuthorExt(id=1329837543798977348, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329837540615500591, authorId=1329837543652176705, language=CN, stringName=李茜, firstName=null, middleName=null, lastName=null, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=*, address=南京医科大学附属第一医院药学部,江苏 南京 210029, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null)}, companyList=[AuthorCompany(id=1329837541408224050, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329837540615500591, xref=null, ext=[AuthorCompanyExt(id=1329837541416612659, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329837540615500591, companyId=1329837541408224050, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=Department of Pharmacy, the First Affiliated Hospital of Nanjing Medical University, Nanjing 210029, Jiangsu Province, China), AuthorCompanyExt(id=1329837541429195572, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329837540615500591, companyId=1329837541408224050, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=南京医科大学附属第一医院药学部,江苏 南京 210029)])])], keywords=[Keyword(id=1329837543908029253, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329837540615500591, language=EN, orderNo=1, keyword=lorlatinib), Keyword(id=1329837543987721030, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329837540615500591, language=EN, orderNo=2, keyword=non-small cell lung cancer), Keyword(id=1329837544067412807, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329837540615500591, language=EN, orderNo=3, keyword=rapid health technology assessment), Keyword(id=1329837544142910280, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329837540615500591, language=CN, orderNo=1, keyword=洛拉替尼), Keyword(id=1329837544210019145, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329837540615500591, language=CN, orderNo=2, keyword=非小细胞肺癌), Keyword(id=1329837544268739402, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329837540615500591, language=CN, orderNo=3, keyword=快速卫生技术评估)], refs=[Reference(id=1329837544361014091, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329837540615500591, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[1], rfOrder=0, authorNames=null, journalName=null, refType=null, unstructuredReference=Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2021, 71(3): 209-249., articleTitle=null, refAbstract=null), Reference(id=1329837544436511564, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329837540615500591, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[2], rfOrder=1, authorNames=null, journalName=null, refType=null, unstructuredReference=Zheng R, Zhang S, Zeng H, et al. Cancer incidence and mortality in China, 2016[J]. JNCC, 2022, 2(1): 1-9., articleTitle=null, refAbstract=null), Reference(id=1329837544516203341, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329837540615500591, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[3], rfOrder=2, authorNames=null, journalName=null, refType=null, unstructuredReference=Baba K, Goto Y. Lorlatinib as a treatment for ALK-positive lung cancer[J]. Future Oncol, 2022, 18(24): 2745-2766., articleTitle=null, refAbstract=null), Reference(id=1329837544600089422, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329837540615500591, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[4], rfOrder=3, authorNames=null, journalName=null, refType=null, unstructuredReference=Rothenstein JM, Chooback N. ALK inhibitors, resistance development, clinical trials[J]. Curr Oncol, 2018, 25(Suppl 1): S59-S67., articleTitle=null, refAbstract=null), Reference(id=1329837544700752719, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329837540615500591, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[5], rfOrder=4, authorNames=null, journalName=null, refType=null, unstructuredReference=Syed YY. Lorlatinib: first global approval[J]. Drugs, 2019, 79(1): 93-98., articleTitle=null, refAbstract=null), Reference(id=1329837544780444496, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329837540615500591, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[6], rfOrder=5, authorNames=null, journalName=null, refType=null, unstructuredReference=De Abreu Lourenco R, Williams S. Health technology assessment and health care utilisation in the management of early prostate cancer[J]. Eur Urol Focus, 2019, 5(2): 134-136., articleTitle=null, refAbstract=null), Reference(id=1329837544881107793, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329837540615500591, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[7], rfOrder=6, authorNames=null, journalName=null, refType=null, unstructuredReference=Shea BJ, Reeves BC, Wells G, et al. AMSTAR 2: a critical appraisal tool for systematic reviews that include randomised or non-randomised studies of healthcare interventions, or both[J]. BMJ, 2017, 358: j4008., articleTitle=null, refAbstract=null), Reference(id=1329837544952410962, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329837540615500591, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[8], rfOrder=7, authorNames=null, journalName=null, refType=null, unstructuredReference=Li N, Zheng H, Zheng B, et al. Economic evaluations of immune checkpoint inhibitors for patients with non-small cell lung cancer: a systematic review[J]. Cancer Manag Res, 2020, 12: 4503-4518., articleTitle=null, refAbstract=null), Reference(id=1329837545036297044, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329837540615500591, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[9], rfOrder=8, authorNames=null, journalName=null, refType=null, unstructuredReference=王青, 赵璐, 吴尚, 等. 劳拉替尼治疗非小细胞肺癌临床疗效的meta分析及其安全性评价[J]. 中国医院用药评价与分析, 2023, 23(2): 212-218., articleTitle=null, refAbstract=null), Reference(id=1329837545099211605, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329837540615500591, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[10], rfOrder=9, authorNames=null, journalName=null, refType=null, unstructuredReference=Peng Y, Zhao Q, Liao Z, et al. Efficacy and safety of first-line treatments for patients with advanced anaplastic lymphoma kinase mutated, non-small cell cancer: a systematic review and network meta-analysis[J]. Cancer, 2023, 129(8): 1261-1275., articleTitle=null, refAbstract=null), Reference(id=1329837545178903382, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329837540615500591, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[11], rfOrder=10, authorNames=null, journalName=null, refType=null, unstructuredReference=Wen Y, Jiang T, Wu X, et al. Front-line treatment for advanced non-small-cell lung cancer and ALK fusion: a network meta-analysis[J]. Ther Adv Med Oncol, 2022, 14: 17588359221116607., articleTitle=null, refAbstract=null), Reference(id=1329837545258595159, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329837540615500591, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[12], rfOrder=11, authorNames=null, journalName=null, refType=null, unstructuredReference=Tao J, Zheng C, Zhang C, et al. First-line treatments for patients with advanced ALK gene rearrangements in NSCLC: a systematic review and network meta-analysis[J]. J Int Med Res, 2022, 50(11): 3000605221132703., articleTitle=null, refAbstract=null), Reference(id=1329837545338286936, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329837540615500591, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[13], rfOrder=12, authorNames=null, journalName=null, refType=null, unstructuredReference=Ma HC, Liu YH, Ding KL, et al. Comparative efficacy and safety of first-line treatments for advanced non-small cell lung cancer with ALK-rearranged: a meta-analysis of clinical trials[J]. BMC Cancer, 2021, 21(1): 1278., articleTitle=null, refAbstract=null), Reference(id=1329837545426367321, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329837540615500591, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[14], rfOrder=13, authorNames=null, journalName=null, refType=null, unstructuredReference=Chuang CH, Chen HL, Chang HM, et al. Systematic review and network meta-analysis of anaplastic lymphoma kinase (ALK) inhibitors for treatment-naïve ALK-positive lung cancer[J]. Cancers (Basel), 2021, 13(8): 1966., articleTitle=null, refAbstract=null), Reference(id=1329837545506059098, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329837540615500591, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[15], rfOrder=14, authorNames=null, journalName=null, refType=null, unstructuredReference=Ando K, Manabe R, Kishino Y, et al. Comparative efficacy and safety of lorlatinib and alectinib for ALK-rearrangement positive advanced non-small cell lung cancer in asian and non-asian patients: a systematic review and network meta-analysis[J]. Cancers (Basel), 2021, 13(15): 3704., articleTitle=null, refAbstract=null), Reference(id=1329837545606722395, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329837540615500591, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[16], rfOrder=15, authorNames=null, journalName=null, refType=null, unstructuredReference=Wang L, Sheng Z, Zhang J, et al. Comparison of lorlatinib, alectinib and brigatinib in ALK inhibitor-naive/untreated ALK-positive advanced non-small-cell lung cancer: a systematic review and network meta-analysis[J]. J Chemother, 2022, 34(2): 87-96., articleTitle=null, refAbstract=null), Reference(id=1329837545673831260, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329837540615500591, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[17], rfOrder=16, authorNames=null, journalName=null, refType=null, unstructuredReference=Peng L, Lu D, Xia Y, et al. Efficacy and safety of first-line treatment strategies for anaplastic lymphoma kinase-positive non-small cell lung cancer: a bayesian network meta-analysis[J]. Front Oncol, 2021, 11: 754768., articleTitle=null, refAbstract=null), Reference(id=1329837545824826205, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329837540615500591, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[18], rfOrder=17, authorNames=null, journalName=null, refType=null, unstructuredReference=齐冉, 刘旭婷, 高胜男, 等. 劳拉替尼与阿来替尼一线治疗间变性淋巴瘤激酶阳性非小细胞肺癌的药物经济学评价[J]. 中国药业, 2023, 32(5): 115-119., articleTitle=null, refAbstract=null), Reference(id=1329837545896129374, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329837540615500591, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[19], rfOrder=18, authorNames=null, journalName=null, refType=null, unstructuredReference=孙蕾, 陈平钰, 马爱霞. 劳拉替尼一线治疗间变性淋巴瘤激酶阳性晚期非小细胞肺癌的药物经济学评价[J]. 中国药房, 2022, 33(9): 1102-1108., articleTitle=null, refAbstract=null), Reference(id=1329837545959043935, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329837540615500591, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[20], rfOrder=19, authorNames=null, journalName=null, refType=null, unstructuredReference=Luo X, Zhou Z, Zeng X, et al. Cost-effectiveness of ensartinib, crizotinib, ceritinib, alectinib, brigatinib and lorlatinib in patients with anaplastic lymphoma kinase-positive non-small cell lung cancer in China[J]. Front Public Health, 2022, 10: 985834., articleTitle=null, refAbstract=null), Reference(id=1329837546026152800, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329837540615500591, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[21], rfOrder=20, authorNames=null, journalName=null, refType=null, unstructuredReference=Li S, Li J, Peng L, et al. Cost-effectiveness of lorlatinib as a first-line therapy for untreated advanced anaplastic lymphoma kinase-positive non-small cell lung cancer[J]. Front Oncol, 2021, 11: 684073., articleTitle=null, refAbstract=null), Reference(id=1329837546164564833, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329837540615500591, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[22], rfOrder=21, authorNames=null, journalName=null, refType=null, unstructuredReference=Thumallapally N, Yu H, Farhan M, et al. Concomitant presence of EGFR and ALK fusion gene mutation in adenocarcinoma of lung: a case report and review of the literature[J]. J Pharm Pract, 2018, 31(2): 244-248., articleTitle=null, refAbstract=null), Reference(id=1329837547695485794, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329837540615500591, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[23], rfOrder=22, authorNames=null, journalName=null, refType=null, unstructuredReference=Solomon BJ, Bauer TM, Ignatius Ou SH, et al. Post hoc analysis of lorlatinib intracranial efficacy and safety in patients with ALK-positive advanced non-small-cell lung cancer from the phase Ⅲ CROWN study[J]. J Clin Oncol, 2022, 40(31): 3593-3602., articleTitle=null, refAbstract=null)], funds=null, companyList=[AuthorCompany(id=1329837541408224050, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329837540615500591, xref=null, ext=[AuthorCompanyExt(id=1329837541416612659, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329837540615500591, companyId=1329837541408224050, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=Department of Pharmacy, the First Affiliated Hospital of Nanjing Medical University, Nanjing 210029, Jiangsu Province, China), AuthorCompanyExt(id=1329837541429195572, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329837540615500591, companyId=1329837541408224050, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=南京医科大学附属第一医院药学部,江苏 南京 210029)])], figs=null, attaches=null, journal=Journal(id=1319689997550452896, delFlag=0, nameCn=世界临床药物, nameEn=World Clinical Drug, nameHistory1=null, nameHistory2=null, issn=1672-9188, eissn=null, cn=31-1939/R, coden=SLYHAA, periodic=0, language=CN, oaType=null, ccby=null, superviseOffice=null, ownerOffice=null, pubOffice=null, editorOffice=null, officeType=null, aims=null, clcCode=null, officeProv=null, officeCity=null, officeAddr=null, officeZip=null, officeEmail=null, officePhone=null, editDirector=null, officeDirector=null, officeDirectorPhone=null, officeStaffNum=null, officeEmpNum=null, coverPicUrl=9c6IkcJKa1cF20h1u6lJeQ==, journalPrice=null, startedYear=null, abbrevIsoEn=World Clinical Drug, journalRemark=null, publicationField=null, createdTime=1792568214072, updatedTime=1792747519563, createdBy=18614031015, updatedBy=13701087609, firstLetterCn=S, firstLetterEn=S, subjectCode=Medical and Pharmaceutical Sciences, subjectName=null, subjectCodeEn=Medical and Pharmaceutical Sciences, subjectNameEn=null, picCn=9c6IkcJKa1cF20h1u6lJeQ==, picEn=MRqUlTwfL6oqIHNy7eyFZQ==, jcr=null, cjcr=null, exts=[JournalExt(id=1320442059660570919, language=CN, name=世界临床药物, nameHistory1=null, nameHistory2=null, managedBy=, sponsoredBy=, publishedBy=, editorOffice=, officeProv=null, officeCity=null, officeAddr=, officeZip=, editDirector=, officeDirector=null, officePhone=null, coverPicUrl=null, journalRemark=, submitArticleUrl=null, websiteUrl=, createdTime=1792747519650, updatedTime=1792747519650, createdBy=13701087609, updatedBy=13701087609, submissionGuidelinesUrl=, submissionAuthorUrl=http://www.jwph.com.cn/journalx_sjlcyw/authorLogOn.action, submissionEditorUrl=http://www.jwph.com.cn/journalx_sjlcyw/editorLogOn.action, submissionReviewUrl=http://www.jwph.com.cn/journalx_sjlcyw/expertLogOn.action, submissionCeEditorUrl=http://www.jwph.com.cn/journalx_sjlcyw/editorInChiefLogOn.action, submissionAeEditorUrl=, option={"copyright":""}), JournalExt(id=1320442059723485480, language=EN, name=World Clinical Drug, nameHistory1=null, nameHistory2=null, managedBy=, sponsoredBy=, publishedBy=, editorOffice=, officeProv=null, officeCity=null, officeAddr=, officeZip=, editDirector=, officeDirector=null, officePhone=null, coverPicUrl=null, journalRemark=, submitArticleUrl=null, websiteUrl=, createdTime=1792747519665, updatedTime=1792747519665, createdBy=13701087609, updatedBy=13701087609, submissionGuidelinesUrl=, submissionAuthorUrl=http://www.jwph.com.cn/journalx_sjlcyw/authorLogOn.action, submissionEditorUrl=http://www.jwph.com.cn/journalx_sjlcyw/editorLogOn.action, submissionReviewUrl=http://www.jwph.com.cn/journalx_sjlcyw/expertLogOn.action, submissionCeEditorUrl=http://www.jwph.com.cn/journalx_sjlcyw/editorInChiefLogOn.action, submissionAeEditorUrl=, option={"copyright":""})], databaseList=null, tenantJournalId=1319690329412173987, websiteList=[Website(id=1321427104911179915, webName=null, webTitle=null, webDomain=null, webCopyrigh=null, webIpcNo=null, seoTitle=null, seoKeywords=null, seoDescription=null, tenantJournalId=null, journalId=1319690329412173987, journalNameCn=null, journalNameEn=null, grayFlag=null, tenantId=1146029695717560320, platformId=null, journalGroupId=null, journalGroupNameCn=null, journalGroupNameEn=null, type=1, domain=https://castjournals.cast.org.cn/joweb/sjlcyw/CN, language=CN, createTime=1792982372739, createBy=18614031015, updateTime=1792982514949, updateBy=18614031015, name=世界临床药物-中文, tplId=1146099689490845704, title=世界临床药物, delFlag=0, indexPage=/home, props=[WebsiteProps(id=1321428428256031726, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104911179915, code=articleTextType, value=kx, createTime=1792982688249, updateTime=1792982688249, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428428193117163, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104911179915, code=banner, value=https://castjournals.cast.org.cn/joweb/sjlcyw/CN/file/pic?fileId=RR/csUBcM48ejcuaaK5s0g==, createTime=1792982688234, updateTime=1792982688234, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428428302169073, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104911179915, code=grayFlag, value=0, createTime=1792982688260, updateTime=1792982688260, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428428172145642, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104911179915, code=logo, value=https://castjournals.cast.org.cn/joweb/sjlcyw/CN/file/pic?fileId=yyY2emcxcV1CfIeK9tH8ZA==, createTime=1792982688229, updateTime=1792982688229, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428428327334899, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104911179915, code=minRunFlag, value=0, createTime=1792982688266, updateTime=1792982688266, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428428226671597, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104911179915, code=picServerUrl, value=https://castjournals.cast.org.cn/joweb/sjlcyw/CN/file/pic, createTime=1792982688242, updateTime=1792982688242, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428428314751986, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104911179915, code=silenceFlag, value=0, createTime=1792982688263, updateTime=1792982688263, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428428209894380, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104911179915, code=staticResourcePath, value=https://castjournals.cast.org.cn/joweb/cast_kjdb_cn_619/, createTime=1792982688238, updateTime=1792982688238, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428428268614639, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104911179915, code=themeColor, value=null, createTime=1792982688252, updateTime=1792982688252, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428428289586160, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104911179915, code=themeStyle, value=.style-1 .main-menu ul>li { margin-right: 18px; } @media (max-width: 1442px) { .style-1 .main-menu ul>li a { font-size: 16px; padding: 10px 0; } }, createTime=1792982688257, updateTime=1792982688257, creator=18614031015, updator=18614031015)]), Website(id=1321427104990871693, webName=null, webTitle=null, webDomain=null, webCopyrigh=null, webIpcNo=null, seoTitle=null, seoKeywords=null, seoDescription=null, tenantJournalId=null, journalId=1319690329412173987, journalNameCn=null, journalNameEn=null, grayFlag=null, tenantId=1146029695717560320, platformId=null, journalGroupId=null, journalGroupNameCn=null, journalGroupNameEn=null, type=1, domain=https://castjournals.cast.org.cn/joweb/sjlcyw/EN, language=EN, createTime=1792982372758, createBy=18614031015, updateTime=1792982556355, updateBy=18614031015, name=世界临床药物-英文, tplId=1146101810881728533, title=World Clinical Drug, delFlag=0, indexPage=/home, props=[WebsiteProps(id=1321428446820021244, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104990871693, code=articleTextType, value=kx, createTime=1792982692675, updateTime=1792982692675, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428446757106681, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104990871693, code=banner, value=https://castjournals.cast.org.cn/joweb/sjlcyw/EN/file/pic?fileId=RR/csUBcM48ejcuaaK5s0g==, createTime=1792982692660, updateTime=1792982692660, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428447109428223, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104990871693, code=grayFlag, value=0, createTime=1792982692744, updateTime=1792982692744, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428446736135160, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104990871693, code=logo, value=https://castjournals.cast.org.cn/joweb/sjlcyw/EN/file/pic?fileId=yyY2emcxcV1CfIeK9tH8ZA==, createTime=1792982692655, updateTime=1792982692655, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428447142981632, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104990871693, code=minRunFlag, value=0, createTime=1792982692752, updateTime=1792982692752, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428446790661115, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104990871693, code=picServerUrl, value=https://castjournals.cast.org.cn/joweb/sjlcyw/EN/file/pic, createTime=1792982692668, updateTime=1792982692668, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428447130399745, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104990871693, code=silenceFlag, value=0, createTime=1792982692749, updateTime=1792982692749, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428446769689594, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104990871693, code=staticResourcePath, value=https://castjournals.cast.org.cn/joweb/cast_kjdb_en_623/, createTime=1792982692663, updateTime=1792982692663, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428446832604157, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104990871693, code=themeColor, value=null, createTime=1792982692678, updateTime=1792982692678, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428447092651006, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104990871693, code=themeStyle, value=.style-1 .main-menu ul>li { margin-right: 18px; } @media (max-width: 1442px) { .style-1 .main-menu ul>li a { font-size: 16px; padding: 10px 0; } }, createTime=1792982692740, updateTime=1792982692740, creator=18614031015, updator=18614031015)])], journalTitle=世界临床药物, weixinUrl=null, journalUrl=http://www.jwph.com.cn/, iacademicId=null, status=1, seqNo=null, journalTitleEn=World Clinical Drug, journalPhotoCn=9c6IkcJKa1cF20h1u6lJeQ==, journalPhotoEn=MRqUlTwfL6oqIHNy7eyFZQ==, journalFirstLetter=S, journalRecommend=null, journalNew=null, journalCollection=null, jcrJf=null, cjcrJf=null, jcrJfStr=null, cjcrJfStr=null, submissionFirstDecision=null, sciSubjectClassification=null, casSubjectClassification=null, citeScore=null, totalCitationFrequency=null, icpCode=null, psCode=null, advertisingLicenseCode=null, copyrightInformation=null, country=null, option=, provinceCode=null, provinceName=null, collectFlag=false, interPubPlatform=, interPubPlatformUrl=null), detailUrlCn=https://castjournals.cast.org.cn/joweb/sjlcyw/CN/10.13683/j.wph.2024.03.013, detailUrlEn=https://castjournals.cast.org.cn/joweb/sjlcyw/EN/10.13683/j.wph.2024.03.013, pdfUrlCn=https://castjournals.cast.org.cn/joweb/sjlcyw/CN/PDF/10.13683/j.wph.2024.03.013, pdfUrlEn=https://castjournals.cast.org.cn/joweb/sjlcyw/EN/PDF/10.13683/j.wph.2024.03.013, aliStartDate=0, aliEndDate=0, collectionFlag=false, citedCount=null, citedUrl=null, previewStatus=0, delFlag=0, hasFullText=0, orderTime=1710000000000, fullTextJson=null, articleText=null, reference=null)
收藏切换
洛拉替尼一线治疗间变性淋巴瘤激酶突变阳性非小细胞肺癌患者的快速卫生技术评估
闫雨婷 , 孙洁雨 , 李茜 *
世界临床药物 | 研究论文 2024,45(3): 317-323
收起
收藏切换
世界临床药物 |研究论文 2024 , 45 (3) : 317 -323
洛拉替尼一线治疗间变性淋巴瘤激酶突变阳性非小细胞肺癌患者的快速卫生技术评估
全屏
[Author(id=1329837541496304438, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329837540615500591, orderNo=0, firstName=null, middleName=null, lastName=null, nameCn=null, orcid=null, stid=null, country=null, authorPic=null, dead=0, email=null, emailSecond=null, emailThird=null, correspondingAuthor=0, authorType=1, ext={EN=AuthorExt(id=1329837541571801912, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329837540615500591, authorId=1329837541496304438, language=EN, stringName=Yuting YAN, firstName=Yuting, middleName=null, lastName=YAN, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=null, address=Department of Pharmacy, the First Affiliated Hospital of Nanjing Medical University, Nanjing 210029, Jiangsu Province, China, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null), CN=AuthorExt(id=1329837541672465209, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329837540615500591, authorId=1329837541496304438, language=CN, stringName=闫雨婷, firstName=null, middleName=null, lastName=null, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=null, address=南京医科大学附属第一医院药学部,江苏 南京 210029, bio={"content":"

闫雨婷,主管药师,研究方向:抗肿瘤药物合理应用。

"}, bioImg=null, bioContent=

闫雨婷,主管药师,研究方向:抗肿瘤药物合理应用。

, aboutCorrespAuthor=null)}, companyList=[AuthorCompany(id=1329837541408224050, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329837540615500591, xref=null, ext=[AuthorCompanyExt(id=1329837541416612659, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329837540615500591, companyId=1329837541408224050, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=Department of Pharmacy, the First Affiliated Hospital of Nanjing Medical University, Nanjing 210029, Jiangsu Province, China), AuthorCompanyExt(id=1329837541429195572, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329837540615500591, companyId=1329837541408224050, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=南京医科大学附属第一医院药学部,江苏 南京 210029)])]), Author(id=1329837543295660859, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329837540615500591, orderNo=1, firstName=null, middleName=null, lastName=null, nameCn=null, orcid=null, stid=null, country=null, authorPic=null, dead=0, email=null, emailSecond=null, emailThird=null, correspondingAuthor=0, authorType=1, ext={EN=AuthorExt(id=1329837543387935550, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329837540615500591, authorId=1329837543295660859, language=EN, stringName=Jieyu SUN, firstName=Jieyu, middleName=null, lastName=SUN, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=null, address=Department of Pharmacy, the First Affiliated Hospital of Nanjing Medical University, Nanjing 210029, Jiangsu Province, China, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null), CN=AuthorExt(id=1329837543530541887, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329837540615500591, authorId=1329837543295660859, language=CN, stringName=孙洁雨, firstName=null, middleName=null, lastName=null, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=null, address=南京医科大学附属第一医院药学部,江苏 南京 210029, bio={"content":"

孙洁雨,主管药师,研究方向:循证药学。

"}, bioImg=null, bioContent=

孙洁雨,主管药师,研究方向:循证药学。

, aboutCorrespAuthor=null)}, companyList=[AuthorCompany(id=1329837541408224050, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329837540615500591, xref=null, ext=[AuthorCompanyExt(id=1329837541416612659, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329837540615500591, companyId=1329837541408224050, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=Department of Pharmacy, the First Affiliated Hospital of Nanjing Medical University, Nanjing 210029, Jiangsu Province, China), AuthorCompanyExt(id=1329837541429195572, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329837540615500591, companyId=1329837541408224050, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=南京医科大学附属第一医院药学部,江苏 南京 210029)])]), Author(id=1329837543652176705, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329837540615500591, orderNo=2, firstName=null, middleName=null, lastName=null, nameCn=null, orcid=null, stid=null, country=null, authorPic=null, dead=0, email=null, emailSecond=null, emailThird=null, correspondingAuthor=1, authorType=1, ext={EN=AuthorExt(id=1329837543731868483, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329837540615500591, authorId=1329837543652176705, language=EN, stringName=Qian LI, firstName=Qian, middleName=null, lastName=LI, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=*, address=Department of Pharmacy, the First Affiliated Hospital of Nanjing Medical University, Nanjing 210029, Jiangsu Province, China, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null), CN=AuthorExt(id=1329837543798977348, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329837540615500591, authorId=1329837543652176705, language=CN, stringName=李茜, firstName=null, middleName=null, lastName=null, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=*, address=南京医科大学附属第一医院药学部,江苏 南京 210029, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null)}, companyList=[AuthorCompany(id=1329837541408224050, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329837540615500591, xref=null, ext=[AuthorCompanyExt(id=1329837541416612659, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329837540615500591, companyId=1329837541408224050, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=Department of Pharmacy, the First Affiliated Hospital of Nanjing Medical University, Nanjing 210029, Jiangsu Province, China), AuthorCompanyExt(id=1329837541429195572, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329837540615500591, companyId=1329837541408224050, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=南京医科大学附属第一医院药学部,江苏 南京 210029)])])]
闫雨婷, 孙洁雨, 李茜*
作者信息
  • 南京医科大学附属第一医院药学部,江苏 南京 210029
通讯作者:
李茜,主管药师,研究方向:医院药学。
作者简介:

闫雨婷,主管药师,研究方向:抗肿瘤药物合理应用。

孙洁雨,主管药师,研究方向:循证药学。

Rapid health technology assessment of lorlatinib in the first-line treatment of anaplastic lymphoma kinase mutation-positive non-small cell lung cancer
Yuting YAN, Jieyu SUN, Qian LI*
Affiliations
  • Department of Pharmacy, the First Affiliated Hospital of Nanjing Medical University, Nanjing 210029, Jiangsu Province, China
出版时间: 2024-03-10 doi: 10.13683/j.wph.2024.03.013
文章导航
收藏切换
目的

应用快速卫生技术评估(rapid health technology assessment,rHTA)对洛拉替尼一线治疗间变性淋巴瘤激酶(anaplastic lymphoma kinase,ALK)突变阳性非小细胞肺癌(non-small cell lung cancer,NSCLC)患者的安全性、有效性及经济性进行评估,为临床决策者提供药品遴选循证依据。

方法

检索国内外数据库及全球各大HTA官方网站,纳入洛拉替尼一线治疗ALK突变阳性NSCLC患者相关文献,并进行综合性分析。

结果

共纳入9篇系统评价/meta分析、4篇经济学研究。有效性结果显示,洛拉替尼客观缓解率和无进展生存期显著优于其他ALK-酪氨酸激酶抑制剂和化学药物,但总生存率无显著差异;安全性结果显示,洛拉替尼≥3级不良反应事件发生率仅低于塞瑞替尼,但均可控;经济性结果未显示出显著成本-效果优势。

结论

洛拉替尼一线治疗ALK突变阳性NSCLC患者具有有效性、安全性优势,但其经济性优势需进一步研究,未来有必要开展更直观的比较,并进行多亚组的安全性、有效性及经济性研究。

洛拉替尼  /  非小细胞肺癌  /  快速卫生技术评估
Objective

To evaluate the safety, efficacy and economy of lorlatinib as the first-line treatment in patients with anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC) by rapid health technology assessment (rHTA), and to provide evidence for clinical decision makers.

Methods

Domestic and foreign databases and other major official HTA websites were used, and the related literatures about lorlatinib as first-line treatment for ALK mutation-positive NSCLC patients were included and comprehensively analyzed.

Results

A total of 9 systematic/meta-analyses and 4 economic studies were included. Efficacy results showed that objective response rate and progression-free survival of lorlatinib were significantly better than other ALK-tyrosine kinase inhibitors and chemicals, but overall survival was not significantly different. Safety results showed that the incidence of adverse events of lorlatinib≥3 was only lower than ceritinib, but controllable. Economic results did not show a significant cost-effectiveness advantage.

Conclusion

Lorlatinib has efficacy and safety advantages in the first-line treatment of ALK mutation-positive NSCLC patients, but its economic advantages need to be further studied. More safety, effectiveness and economic studies focusing on intuitive comparison and multi-subgroup are necessary.

lorlatinib  /  non-small cell lung cancer  /  rapid health technology assessment
闫雨婷, 孙洁雨, 李茜. 洛拉替尼一线治疗间变性淋巴瘤激酶突变阳性非小细胞肺癌患者的快速卫生技术评估. 世界临床药物, 2024 , 45 (3) : 317 -323 . DOI: 10.13683/j.wph.2024.03.013
Yuting YAN, Jieyu SUN, Qian LI. Rapid health technology assessment of lorlatinib in the first-line treatment of anaplastic lymphoma kinase mutation-positive non-small cell lung cancer[J]. World Clinical Drug, 2024 , 45 (3) : 317 -323 . DOI: 10.13683/j.wph.2024.03.013

参考文献 引证文献
排序方式:
[1]
Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2021, 71(3): 209-249.
[2]
Zheng R, Zhang S, Zeng H, et al. Cancer incidence and mortality in China, 2016[J]. JNCC, 2022, 2(1): 1-9.
[3]
Baba K, Goto Y. Lorlatinib as a treatment for ALK-positive lung cancer[J]. Future Oncol, 2022, 18(24): 2745-2766.
[4]
Rothenstein JM, Chooback N. ALK inhibitors, resistance development, clinical trials[J]. Curr Oncol, 2018, 25(Suppl 1): S59-S67.
[5]
Syed YY. Lorlatinib: first global approval[J]. Drugs, 2019, 79(1): 93-98.
[6]
De Abreu Lourenco R, Williams S. Health technology assessment and health care utilisation in the management of early prostate cancer[J]. Eur Urol Focus, 2019, 5(2): 134-136.
[7]
Shea BJ, Reeves BC, Wells G, et al. AMSTAR 2: a critical appraisal tool for systematic reviews that include randomised or non-randomised studies of healthcare interventions, or both[J]. BMJ, 2017, 358: j4008.
[8]
Li N, Zheng H, Zheng B, et al. Economic evaluations of immune checkpoint inhibitors for patients with non-small cell lung cancer: a systematic review[J]. Cancer Manag Res, 2020, 12: 4503-4518.
[9]
王青, 赵璐, 吴尚, 等. 劳拉替尼治疗非小细胞肺癌临床疗效的meta分析及其安全性评价[J]. 中国医院用药评价与分析, 2023, 23(2): 212-218.
[10]
Peng Y, Zhao Q, Liao Z, et al. Efficacy and safety of first-line treatments for patients with advanced anaplastic lymphoma kinase mutated, non-small cell cancer: a systematic review and network meta-analysis[J]. Cancer, 2023, 129(8): 1261-1275.
[11]
Wen Y, Jiang T, Wu X, et al. Front-line treatment for advanced non-small-cell lung cancer and ALK fusion: a network meta-analysis[J]. Ther Adv Med Oncol, 2022, 14: 17588359221116607.
[12]
Tao J, Zheng C, Zhang C, et al. First-line treatments for patients with advanced ALK gene rearrangements in NSCLC: a systematic review and network meta-analysis[J]. J Int Med Res, 2022, 50(11): 3000605221132703.
[13]
Ma HC, Liu YH, Ding KL, et al. Comparative efficacy and safety of first-line treatments for advanced non-small cell lung cancer with ALK-rearranged: a meta-analysis of clinical trials[J]. BMC Cancer, 2021, 21(1): 1278.
[14]
Chuang CH, Chen HL, Chang HM, et al. Systematic review and network meta-analysis of anaplastic lymphoma kinase (ALK) inhibitors for treatment-naïve ALK-positive lung cancer[J]. Cancers (Basel), 2021, 13(8): 1966.
[15]
Ando K, Manabe R, Kishino Y, et al. Comparative efficacy and safety of lorlatinib and alectinib for ALK-rearrangement positive advanced non-small cell lung cancer in asian and non-asian patients: a systematic review and network meta-analysis[J]. Cancers (Basel), 2021, 13(15): 3704.
[16]
Wang L, Sheng Z, Zhang J, et al. Comparison of lorlatinib, alectinib and brigatinib in ALK inhibitor-naive/untreated ALK-positive advanced non-small-cell lung cancer: a systematic review and network meta-analysis[J]. J Chemother, 2022, 34(2): 87-96.
[17]
Peng L, Lu D, Xia Y, et al. Efficacy and safety of first-line treatment strategies for anaplastic lymphoma kinase-positive non-small cell lung cancer: a bayesian network meta-analysis[J]. Front Oncol, 2021, 11: 754768.
[18]
齐冉, 刘旭婷, 高胜男, 等. 劳拉替尼与阿来替尼一线治疗间变性淋巴瘤激酶阳性非小细胞肺癌的药物经济学评价[J]. 中国药业, 2023, 32(5): 115-119.
[19]
孙蕾, 陈平钰, 马爱霞. 劳拉替尼一线治疗间变性淋巴瘤激酶阳性晚期非小细胞肺癌的药物经济学评价[J]. 中国药房, 2022, 33(9): 1102-1108.
[20]
Luo X, Zhou Z, Zeng X, et al. Cost-effectiveness of ensartinib, crizotinib, ceritinib, alectinib, brigatinib and lorlatinib in patients with anaplastic lymphoma kinase-positive non-small cell lung cancer in China[J]. Front Public Health, 2022, 10: 985834.
[21]
Li S, Li J, Peng L, et al. Cost-effectiveness of lorlatinib as a first-line therapy for untreated advanced anaplastic lymphoma kinase-positive non-small cell lung cancer[J]. Front Oncol, 2021, 11: 684073.
[22]
Thumallapally N, Yu H, Farhan M, et al. Concomitant presence of EGFR and ALK fusion gene mutation in adenocarcinoma of lung: a case report and review of the literature[J]. J Pharm Pract, 2018, 31(2): 244-248.
[23]
Solomon BJ, Bauer TM, Ignatius Ou SH, et al. Post hoc analysis of lorlatinib intracranial efficacy and safety in patients with ALK-positive advanced non-small-cell lung cancer from the phase Ⅲ CROWN study[J]. J Clin Oncol, 2022, 40(31): 3593-3602.
2024年第45卷第3期
17
3
0
引用本文
BibTeX
文章信息
doi: 10.13683/j.wph.2024.03.013
  • 接收时间:2023-08-04
  • 首发时间:2026-11-18
  • 出版时间:2024-03-10
补充材料
相关文章
文章信息
作者
出版历史
  • 收稿日期:2023-08-04
基金
作者信息
    南京医科大学附属第一医院药学部,江苏 南京 210029

通讯作者:

李茜,主管药师,研究方向:医院药学。
参考文献
分享链接
https://castjournals.cast.org.cn/joweb/sjlcyw/CN/10.13683/j.wph.2024.03.013
分享至
全文二维码

扫描看全文

引用本文
BibTeX
本文的引用情况
2种不同金属材料的力学参数
科
Family
属数
Number of
genus
种数
Number of
species
占总种数比例
Percentage of
total species (%)
属
Genus
种数
Number of
species
占总种数比例
Percentage of total
species (%)
鹅膏菌科Amanitaceae 2 11 5.26 鹅膏菌属 Amanita 10 4.78
小菇科 Mycenaceae 2 12 5.74 丝盖伞属 Inocybe 5 2.39
多孔菌科 Polyporaceae 8 14 6.70 蜡蘑属 Laccaria 5 2.39
红菇科 Russulaceae 3 23 11.00 小皮伞属 Marasmius 6 2.87
小菇属 Mycena 11 5.26
光柄菇属 Pluteus 5 2.39
红菇属 Russula 17 8.13
栓菌属 Trametes 5 2.39
关闭全屏